The company’s US formulations ... Zydus received FDA approval to conduct Phase II(b) clinical trials of Usnoflast for Amyotrophic Lateral Sclerosis (ALS), which has also received Orphan Drug ...

Zydus Lifesciences Ltd. said on Wednesday that the US Food and Drug Administration granted its underdevelopment drug Usnoflast the orphan drug designation, according to an exchange filing on Wednesday ...

a Vadodara based company with the US FDA approved plant. In the year 2003, German Remedies, Recon Healthcare, Zoom Properties and Zydus Pathline merged with the company. Also, they acquired ...

Zydus Lifesciences: The pharmaceutical company announced the USFDA orphan drug designation to Usnoflast for the treatment ... gets approved. Laurus Labs: The US FDA issued a form 483 with one ...

India's Zydus Lifesciences reported third-quarter profit above analysts' expectations on Wednesday, driven by strong demand for its generic drugs in its key U.S. market.

(Reuters) - India's Zydus Lifesciences reported third-quarter profit above analysts' expectations on Wednesday, driven by strong demand for its generic drugs in its ... helped Zydus Life increase its ...

In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347 ...

In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347 ...

The firm reports a rise of 30 per cent in its consolidated net profit to Rs 1,023 crore, mainly due to robust sales in both domestic and US markets ... crore in Q3FY24. Zydus Life's Earnings ...

US Business Revenue ... growth despite a muted demand scenario. Zydus Lifesciences Ltd (BOM:532321) has a strong innovation pipeline, with FDA approval for a Phase IIb clinical trial of Usnoflast ...

Our robust product portfolio execution in the US ... Director, Zydus Lifesciences Limited, said. The company posted Capex (organic) for the quarter at Rs. 290.7 crore. Zydus Life said that ...